ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Asston Pharmaceuticals Ltd submitted its quarterly shareholding pattern disclosure, detailing the shareholding status of promoters and public shareholders for the period ended March 2026.
Asston Pharmaceuticals has submitted its 7th Annual Report for the financial year 2025-26. The report provides a comprehensive overview of the company's annual financial performance.
Asston Pharmaceuticals Limited announced its Annual General Meeting scheduled for September 29, 2026. The agenda includes adopting financial statements, appointing auditors, and revising remuneration for key managerial personnel.
Asston Pharmaceuticals allotted 24,10,431 equity shares at Rs. 115 per share via preferential allotment, raising Rs. 27.72 Crore. This increases the company's paid-up equity share capital.
Asston Pharmaceuticals announced the outcome of its board meeting, including auditor appointments, director re-appointment, and upcoming AGM scheduling. The board also proposed remuneration increases for directors.
Prakruti R Pali acquired 2,40,000 shares of Asston Pharmaceuticals Ltd through an open market purchase. Post-acquisition stake is 5.33%.
Asston Pharmaceuticals will hold a board meeting on September 4, 2026, to discuss auditor appointment, director remuneration increases, and the upcoming Annual General Meeting.
Asston Pharmaceuticals held an EGM on July 31, 2026. Shareholders approved a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. Shareholders will vote on a special resolution to issue equity shares on a preferential basis.
Asston Pharmaceuticals convened an EGM for July 31, 2026. The agenda includes a Rs. 27.72 Crore preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals approved a Rs.27.72 Crore preferential share issue to non-promoters. An EGM is scheduled for July 31, 2026, for shareholder approval.
Asston Pharmaceuticals scheduled a board meeting for July 2, 2026. The board will consider raising funds via preferential issues.
Asston Pharmaceuticals Ltd reported revenue from operations of ₹10.1 Cr (+11.0% YoY) and net profit of ₹0.5 Cr (-75.0% YoY) for H2 FY26.
Asston Pharmaceuticals approved audited financial results for FY26, reporting a total income of ₹31.58 Crore. The board meeting concluded at 07:10 P.M. on May 29, 2026.
Asston Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited FY26 financial results. This routine regulatory notice precedes official performance disclosures.
Asston Pharmaceuticals Limited confirmed it is not classified as a Large Corporate under SEBI framework for the financial year. The company reported outstanding borrowings of ₹5.04 Crore as of March 31, 2024. This disclosure ensures regulatory compliance regarding debt-raising requirements for listed entities.
Asston Pharmaceuticals Limited conducted an Extraordinary General Meeting on April 28, 2026, via video conferencing. Shareholders considered resolutions including the appointment of M/s Panchal SK & Associates as statutory auditors and the regularization of three directors. The meeting concluded successfully with e-voting facilities provided to members.
Asston Pharmaceuticals Limited announced the voting results of its Extraordinary General Meeting held on April 28, 2026. Shareholders approved the appointment of M/s Panchal SK & Associates as statutory auditors and the regularization of three directors. All resolutions were passed with 100% of the votes cast in favour.
Asston Pharmaceuticals Limited (BSE: 544445) declared the non-applicability of the Annual Secretarial Compliance Report under SEBI (LODR) Regulation 15(2). As an SME-listed entity, the company is exempt from certain corporate governance provisions. The company confirms it will continue to comply with all other applicable listing regulations.